Updates are available Correction dated 2020-05-20
Click to view Correction: https://doi.org/10.1186/s13223-020-00435-z
-
Authors
Langlois, Alexandra
Lavergne, Marie-Hélène
Leroux, Hélène
Killer, Kerstin
Azzano, Pauline
Paradis, Louis
Samaan, Kathryn
Lacombe-Barrios, Jonathan
Eiwegger, Thomas
Upton, Julia
Sussman, Gordon
Poder, Thomas
Mâsse, Benoît
Des Roches, Anne
Bégin, Philippe
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04045301 at ClinicalTrials.govDocuments that mention this clinical trial
Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy
https://doi.org/10.1186/s13223-020-00419-z
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Fondation de l'Hôpital Sainte-Justine
Novartis Pharmaceuticals Canada (In kind)
- License Information
-
More Information
Article History
Received: 29 October 2019
Accepted: 16 March 2020
First Online: 17 April 2020
Change Date: 20 May 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: This trial was approved by the Sainte-Justine Hospital’s Research Ethics Board. All participants will provide informed consent upon recruitment.
: Not applicable.
: The authors declare no conflict of interest related to the study. KS reports personal fees from Novartis outside the submitted work. ADR reports grants from Merk and ALK outside the submitted work. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.
